OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Wong on Next Steps for Validating the Predictive Utility of Molecular Characteristics in CRC

September 2nd 2025

Evelyn Y.T. Wong, MD, discusses discussed the potential use of molecular characteristics to predict survival outcomes in early-onset CRC.

Dr Van Tine on Olaparib Plus Temozolomide in Advanced Uterine Leiomyosarcoma

September 2nd 2025

Brian A. Van Tine, MD, PhD, discussed trial findings with olaparib plus temozolomide in advanced uterine leiomyosarcoma following prior chemotherapy.

Dr Tarhini on the Rationale for Studying Vidutolimod Plus Pembrolizumab in Melanoma

September 2nd 2025

Ahmad Tarhini, MD, PhD, discussed the rationale for evaluating preoperative pembrolizumab plus vidutolimod in macroscopic, resectable stage III melanoma.

Dr Élez on Health-Related QOL With Nivolumab Plus Ipilimumab in mCRC

September 2nd 2025

Elena Élez, MD, PhD, discusses health-related QOL data with nivolumab plus ipilimumab in mCRC.

Dr Olmos on the Prognostic Implications of Data From the CAPTURE Study for BRCA-Mutant mHSPC

September 2nd 2025

David Olmos, MD, PhD, discusses the implications of data from the CAPTURE study for risk stratification in mHSPC harboring BRCA mutations.

Dr Haas on the Rationale for Evaluating Adjuvant Pembrolizumab in Clear Cell RCC

September 2nd 2025

Naomi B. Haas, MD, details the rationale for evaluating adjuvant pembrolizumab monotherapy for the treatment of patients with clear cell RCC.

Dr Raza on Unmet Needs in R/R Myeloma With Extramedullary Disease

September 2nd 2025

Shahzad Raza, MD, highlights the challenges associated with managing relapsed/refractory multiple myeloma with extramedullary disease.

Dr Schlechter on the Potential Future Implications of Botensilimab and Balstilimab in MSS mCRC

September 2nd 2025

Benjamin L. Schlecter, MD, discusses the potential next steps in research for botensilimab for the treatment of patients with metastatic colorectal cancer.

Dr Arafat on Evolving Neoadjuvant Treatment Strategies in MIBC

August 29th 2025

Waddah Arafat, MD, discusses how the use of neoadjuvant chemotherapy in MIBC has changed relative to the addition of immunotherapy to this paradigm.

Dr Hammers on Considerations for Assessing TKI/Immunotherapy Response in ccRCC

August 29th 2025

Hans Hammers, MD, PhD, discusses factors that may influence depth of response to IO/TKI or IO/IO therapy in advanced clear cell renal cell carcinoma.

Dr Landgren on the Rationale for Assessing Daratumumab Plus KRd in Newly Diagnosed Myeloma

August 29th 2025

C. Ola Landgren, MD, PhD, discusses the use of MRD as an early end point in a study evaluating daratumumab plus KRd in newly diagnosed multiple myeloma.

Dr Khan on the Development of Second-Generation BTK Inhibitors in CLL

August 29th 2025

Cyrus M. Khan, MD, detailed the development of second-generation BTK inhibitors and how they compare with first-generation BTK inhibitors in CLL.

Dr Randall on the Identification and Management of Non-Ossifying Fibromas

August 29th 2025

R. Lor Randall, MD, FACS, discusses the management of non-ossifying fibromas, and how this differs from that of malignant tumors.

Dr Desai on Research Informing Upfront CDK 4/6 Inhibitor Use in HR+/HER2– Breast Cancer

August 29th 2025

Neelam Desai, MD, discusses the current body of evidence for CDK 4/6 inhibitor use in metastatic HR-positive, HER2-negative breast cancer.

Dr Mouabbi on Areas for Further Investigation in HER2+ Breast Cancer

August 28th 2025

Jason A. Mouabbi, MD, discusses unmet needs and areas requiring further investigation in HER2-positive advanced breast cancer.

Dr D’Amato on the Rationale for Studying Olaparib/Temozolomide in Leiomyosarcoma

August 28th 2025

Gina Z. D’Amato, MD, discusses the rationale for investigating olaparib plus temozolomide in previously treated advanced uterine leiomyosarcoma.

Dr Vose on the Development of Epcoritamab in Relapsed/Refractory DLBCL

August 28th 2025

Julie M. Vose, MD, MBA, details the rationale for evaluating epcoritamab for the treatment of patients with relapsed/refractory DLBCL with limited options.

Dr Tan on the Management of ADC-Related Toxicities in Breast Cancer

August 28th 2025

Antoinette Tan, MD, MHS, discusses the safety profiles of ADCs and ADC selection considerations for breast cancer.

Dr Necchi on Molecular Data With Perioperative Sacituzumab Govitecan Plus Pembrolizumab in MIBC

August 28th 2025

Andrea Necchi, MD, discusses biomarker data with perioperative sacituzumab govitecan plus pembrolizumab in cisplatin-ineligible MIBC.

Dr Qin on the Design of the HARMONY Trial of Niraparib-Based Therapy in mHSPC

August 28th 2025

Qian (Janie) Qin, MD, discusses the unique design of the phase 2 HARMONY trial of first-line niraparib plus abiraterone acetate and prednisone in mHSPC.